Elder Pharmaceuticals, an integrated healthcare company headquartered in Mumbai, has posted better performance for the first quarter ended June 2007 As per the unaudited provisional results, the income from operations has gone up to Rs 125.25 crore for Q1 as compared to Rs 108.39 crore during the corresponding quarter in the previous year. The profit before tax has gone up to Rs 17.08 crore for Q1 reflecting a growth of 11 per cent over the previous corresponding quarter's figure of Rs15.36 crore. The net profit has gone up to Rs 15.08 cr (previous quarter - Rs 13.11 cr) - a jump of 15 per cent. On an equity capital of Rs 18.57 crore, the EPS on a non - annualised basis comes to Rs 8.12.

The various international alliances of the company, new manufacturing facilities, launch of newer products - particularly in the OTC segment - and strong growth in the traditional products have contributed to the company's better working.

During the quarter, Elder has entered into a strategic in-licensing deal with Cymbiotics Inc., a bio-pharmaceutical company in San Diego, California (USA) for marketing the latter's novel formulations in the areas of pain management, diabetes care, derma care and consumer health products for over the counter sales. The total international in-licensing alliances of Elder now stand at 30.

Elder Pharmaceuticals has presence in niche therapeutic segments like female healthcare, osteoporosis, dermatology, Pain management, Cardiology, diabetology, nutraceuticals and vitamin supplements. Elder is aggressively pursuing its growth plans for the domestic sector and is also looking at right opportunities to make its foray into the global markets - both regulated and non-regulated.